UPDATE: Maxim Group Starts Neurotrope (NTRP) at Buy

(updated to add analyst comment)

Maxim Group initiates coverage on Neurotrope (NASDAQ: NTRP) with a Buy rating and a price target of $16.00.

Analyst Caroline Palomeque comments "By regenerating synapses and attacking AD at its core, we believe that bryostatin could emerge as a viable therapy in AD and potentially have the clinical success that other approaches have not. In our view, positive P2 confirmatory data can position the company well for partnering opportunities or to become an acquisition target for big pharma. Catalysts lay ahead; we see upside at the current ~$70M valuation of the company.."

For an analyst ratings summary and ratings history on Neurotrope click here. For more ratings news on Neurotrope click here.

Shares of Neurotrope closed at $9.04 yesterday.

You May Also Be Interested In

• Freedom Capital Starts Sezzle Inc (SEZL) at Hold
• Lucid Capital Markets Starts Palmer Square Capital BDC (PSBD) at Neutral
• AmerX Starts WidePoint Corp (WYY) at Buy